[Skip to Navigation]
Sign In
February 14, 2007

Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: Questions, Answers, and More Questions

Author Affiliations

Author Affiliations: Duke Clinical Research Institute, Duke Translational Medicine Institute, Durham, NC.

JAMA. 2007;297(6):636-639. doi:10.1001/jama.297.6.636

Contemporary management of acute coronary syndromes (ACS) has advanced in the past decade because of synergies between the tenets of basic science and findings from clinical trials.1 Clinicians, clinical investigators, and patients depend on definitive evidence to promote changes in clinical care. The current challenge is to create a clinical research system that responds to changes in the science with rapid and efficient planning of studies, acquisition of data, analysis, and dissemination of information. Such a system can provide the foundation for continued improvement in clinical care.2

Add or change institution